These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials. Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009 [TBL] [Abstract][Full Text] [Related]
3. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733 [TBL] [Abstract][Full Text] [Related]
5. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Kuschel B; Lux MP; Goecke TO; Beckmann MW Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253 [TBL] [Abstract][Full Text] [Related]
6. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881 [TBL] [Abstract][Full Text] [Related]
7. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800 [TBL] [Abstract][Full Text] [Related]
8. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759 [TBL] [Abstract][Full Text] [Related]
9. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition]. Ruiz-Flores P; Calderón-Garcidueñas AL; Barrera-Saldaña HA Rev Invest Clin; 2001; 53(1):46-64. PubMed ID: 11332051 [TBL] [Abstract][Full Text] [Related]
10. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399 [TBL] [Abstract][Full Text] [Related]
11. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
12. [Breakthrough in breast cancer chemoprevention]. Kahán Z; Thurzó L Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784 [TBL] [Abstract][Full Text] [Related]
13. Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers. Heisey RE; Carroll JC; Warner E; McCready DR; Goel V Can Fam Physician; 1999 Jan; 45():114-24. PubMed ID: 10889864 [TBL] [Abstract][Full Text] [Related]
14. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families. Vaziri SA; Krumroy LM; Rostai M; Casey G Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249 [TBL] [Abstract][Full Text] [Related]
15. Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany. Kiechle M; Gross E; Schwarz-Boeger U; Pfisterer J; Jonat W; Gerber WD; Albacht B; Fischer B; Schlegelberger B; Arnold N Hum Mutat; 2000 Dec; 16(6):529-30. PubMed ID: 11102986 [TBL] [Abstract][Full Text] [Related]
16. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669 [TBL] [Abstract][Full Text] [Related]
17. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421 [TBL] [Abstract][Full Text] [Related]
18. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605 [TBL] [Abstract][Full Text] [Related]
19. Genetic susceptibility to breast and ovarian cancer. Skolnick MH; Frank T; Shattuck-Eidens D; Tavtigian S Pathol Biol (Paris); 1997 Mar; 45(3):245-9. PubMed ID: 9296070 [TBL] [Abstract][Full Text] [Related]
20. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]